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Edited by Berend WieringaAbstract Fibroblast growth factor-21 (FGF21) functions as a
metabolic regulator. The FGF21 transcript is reported to be
abundantly expressed in liver, but little is known about the reg-
ulation of FGF21 expression in other tissues. In this study, we
show that levels of FGF21 protein expression were similar in
skeletal muscle and liver from fasted mice. FGF21 transcript
and protein expression were upregulated in gastrocnemius mus-
cle of skeletal muscle-speciﬁc Akt1 transgenic mice. Serum con-
centration of FGF21 was also increased by Akt1 transgene
activation. In cultured skeletal muscle cells, FGF21 expression
and secretion was regulated by insulin, Akt transduction and
LY294002. These data indicate that skeletal muscle is a source
of FGF21 and that its expression is regulated by a phosphatidyli-
nosistol 3-kinase (PI3-kinase)/Akt1 signaling pathway-depen-
dent mechanism.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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mice1. Introduction
Fibroblast growth factor-21 (FGF21) is a member of FGF
super family that is reported to be primarily expressed in liver
and expressed to a lower extent in thymus [1]. Recent evidence
indicates that FGF21 is an important endogenous regulator
for systemic glucose and lipid metabolism. It has been demon-
strated that FGF21 enhances glucose uptake in an insulin-
independent manner and attenuates lipolysis in mouse and hu-
man adipocytes in vitro [2,3]. It has also been shown that
transgenic mice that overexpress FGF21 in liver are resistant
to diet-induced obesity. Therapeutic administration of
FGF21 to diabetic rodents (ob/ob, db/db and DIO mice) or dia-
betic rhesus monkeys improved plasma glucose and lipid pro-
ﬁle to near normal levels, and corrects obesity [2,4,5].
Knockdown of hepatic FGF21 transcript leads to hyperlipid-Abbreviations: DOX, doxycycline; FGF21, ﬁbroblast growth factor-
21; KD, ketogenic diet; PI3-kinase, phosphatidylinositol 3-kinase;
QRT-PCR, quantitative real-time PCR
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overexpression of FGF21 in liver leads to ketone body produc-
tion [7], suggesting that FGF21 functions as a regulator of the
organisms adaptation to starvation. In this regard, hepatic
FGF21 gene expression is regulated by PPARa [6–8]. Further-
more, the FGF21 gene is a direct target of PPARc [9,10], and
the synergy between FGF21 and PPARc pathways was dem-
onstrated in 3T3-L1 adipocytes [11].
Akt1 is serine–threonine protein kinase that is activated by
various extracellular stimuli through a phosphatidylinositol
3-kinase (PI3-kinase) pathway. Numerous studies have impli-
cated Akt in insulin signaling as well as the control of cellular
growth and organ size and cellular hypertrophy [12,13]. Over-
expression of Akt in skeletal muscle results in ﬁber hypertro-
phy in vitro and in vivo [14–16]. We have recently
demonstrated that Akt1-mediated skeletal muscle growth in
obese mice leads to a reduction in accumulated white adipose
tissue and improvements in metabolic parameters [17]. These
ﬁndings led us to the hypothesize that activation of Akt1 sig-
naling in skeletal muscle could lead to the secretion of hor-
monal factors or ‘‘myokines’’ that act on adipose, hepatic or
central nervous system tissues to normalize metabolic parame-
ters. Myokines are deﬁned as proteins that are produced and
secreted from muscle that have paracrine or endocrine func-
tions [18]. While it has been well-established that muscle se-
cretes factors required for blood vessel recruitment [16,19],
the secretion of metabolic-regulatory proteins by this tissue
has only received recent attention. Interleukin-6 is an example
of a myokine that is released into the circulation in response to
exercise and modulates the function of remote metabolically
important tissues [20]. Recently, it was also shown that visfa-
tin, a putative regulator of inﬂammation and glucose metabo-
lism, is produced at higher levels in skeletal muscle than
visceral adipose tissue in chickens [21]. Here, we show that
skeletal muscle is a source of secreted FGF21 and that its
expression is regulated by an Akt1 signaling pathway-depen-
dent mechanism.2. Materials and methods
2.1. Cell culture and adenoviral infection
C2C12 mouse myoblasts (American Type Culture Collection) were
maintained in growth medium (DMEM supplemented with 20%
FBS) as described elsewhere [16]. To induce diﬀerentiation, cells were
shifted to diﬀerentiation medium (DMEM supplemented with 2%
heat-inactivated horse serum) for 4 days. Cells were then infected
with adenoviral constructs encoding constitutively-active Akt1blished by Elsevier B.V. All rights reserved.
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infection (MOI) of 250 for 16 h. The transfection eﬃciency was greater
than 90% under these conditions [16]. In some experiments, C2C12
myocytes were pretreated with LY294002 (20 lmol/L) or vehicle for
1 h before stimulation with insulin (10 nmol/L).2.2. Animals
Generation and phenotypic characterization of skeletal muscle-spe-
ciﬁc inducible Akt1 transgenic (TG) mice have been previously de-
scribed elsewhere in detail [17]. In brief, 1256 [3Emut] MCK-rtTA
TG mice [22] were crossed with TRE-myrAkt1 TG mice [23] to gener-
ate double TG (DTG) mice. For Akt1 transgene expression, DTG
mice were induced with doxycycline (DOX, 0.5 mg/ml) in their drink-
ing water. 1256 [3Emut] MCK-rtTA single TG littermates were treated
with DOX in the same manner as DTG mice and used as controls.
Three weeks after DOX treatment, sera and gastrocnemius muscle
from control or transgenic mice were harvested for mRNA and protein
analysis. For fasting experiments, food pellets were removed from the
cages of ad libitum-fed male C57BL/6 mice for 48 h. Mice were then
anesthetized, gastrocnemius muscles and liver were immediately re-
moved for protein analysis.Fig. 1. Skeletal muscle FGF21 transcript and protein levels are upregul
Microarray analysis of FGF21 transcript regulation in gastrocnemius muscle
weeks after Akt1 transgene activation. (B) Relative transcript expression le
gastrocnemius muscle. (C) Comparable levels of FGF21 protein expression in
for 48 h. (D) Representative western blot analysis and quantiﬁed relative prot
skeletal muscle-speciﬁc Akt1 transgenic mice 3 weeks after transgene indu
inducible Akt1 transgenic mice. Results are presented as mean ± S.E.M. (n
speciﬁc inducible Akt1 transgenic mice.2.3. Determination of FGF21 mRNA
Total RNA was prepared by Qiagen using protocols provided by the
manufacturer and cDNA was produced using ThermoScript RT-PCR
Systems (Invitrogen). Real-time PCR was performed on iCycler iQ
Real-Time PCR Detection System (BIO-RAD). SYBR Green I was
used as a double-stranded DNA-speciﬁc dye as described previously
[24]. Transcript levels were determined relative to the signal from
GAPDH, and normalized to the mean value of samples from control.
Primers were as follows: 5 0-GCTGCTGGAGGACGGTTACA-3 0 and
5 0- CACAGGTCCCCAGGATGTTG-30 for mouse FGF21 and 5 0-
GCTAAGCAGTTGGTGGTGCA-3 0 for mouse GAPDH.
Microarray analysis was carried out as described previously [25].
2.4. Western blots and immunoprecipitations
C2C12 cell lysates, culture media, and skeletal muscle tissue sam-
ples were subjected to SDS–PAGE and Western blot analysis. Anti-
bodies used in Western blots were against: phospho-Akt from Cell
Signaling Technology (Beverly, MA); FGF21 (monoclonal;
clone#84-E12; raised against full length human FGF21 protein);
GAPDH [11]. Immunoprecipitation from lysates was performed
using the same anti-FGF21 antibodies. Immune complexes were
probed with anti-FGF21 (polyclonal; clone PR050928A; raisedated in skeletal muscle-speciﬁc inducible Akt1 transgenic mice. (A)
harvested from skeletal muscle-speciﬁc inducible Akt1 transgenic mice 3
vels of FGF21 as measured by QRT-PCR in control and transgenic
gastrocnemius muscle and liver of wild-type mice that have been fasted
ein expression levels of FGF21 in gastrocnemius muscle from control or
ction. (E) Serum FGF21 levels in control or skeletal muscle-speciﬁc
= 4). *P < 0.05 vs. control. Cont; control mice, TG; skeletal muscle-
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goat anti-mouse and anti-rabbit HRP conjugates were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and the ECL
detection system from Amersham Biosciences (Piscataway, NJ) was
used.Fig. 2. FGF21 transcript and protein levels are upregulated in cultured C2C1
transcript expression in Adeno-myrAkt1-treated C2C12 myocytes cell lysate
FGF21 as measured by QRT-PCR. (C) Representative western blot analysis
bGal or adeno-myrAkt1-treated C2C12 myocyte cell lysates. (D) Represent
levels of FGF21 in C2C12 cell culture media. Results are presented as mean2.5. FGF21 ELISA
Serum samples were measured for concentrations of FGF21 using
anti-FGF21 antibodies by sandwich ELISA method [26]. The wells
of a 96-well microtiter plate were coated overnight at 4 C with mono-
clonal anti-FGF21 antibody at a concentration of 5 lg/mL (0.1 mL/2 myocytes by Akt1 overexpression. (A) Microarray analysis of FGF21
s compared with control. (B) Relative transcript expression levels of
and quantiﬁed relative protein expression levels of FGF21 in adeno-
ative Western blot analysis and quantiﬁed relative protein expression
± S.E.M. (n = 4). *P < 0.05 vs. control.
3808 Y. Izumiya et al. / FEBS Letters 582 (2008) 3805–3810well). All assay steps were carried out in 0.1 mL/well additions with 1 h
incubations at room temperature. After washing and blocking, stan-
dards and samples were added to the wells. Polyclonal anti-FGF21
(1:10000 dilution) was added and detected with a 1:5000 dilution of
donkey-anti-rabbit-HRP from Jackson ImmunoResearch (West
Grove, PA). Samples were analyzed in duplicate. The standard curve
range for the assay was 0.39–50 ng/mL.
2.6. Statistical analyses
All data are presented as mean ± S.E.M. Statistical comparison of
data from two experimental groups were made by using Students t-
test. Comparison of data from multiple groups was made by ANOVA
with Fishers PLSD test. A level of P < 0.05 was accepted as statisti-
cally signiﬁcant.3. Results
3.1. FGF21 induction by Akt signaling in skeletal muscle
Microarray analysis was performed on inducible, skeletal
muscle-speciﬁc Akt1 transgenic mice [17]. The constitu-Fig. 3. FGF21 protein expression is upregulated by insulin, and inhibited
western blot analysis and quantiﬁed relative protein expression levels of FG
LY294002 (20 lmol/L) or vehicle for 1 h before stimulation with insulin (10tively-active Akt1 transgene is under the control of a mu-
tated, muscle creatine kinase promoter [22]. This promoter
construct has little or no activity in type I muscle ﬁbers or
heart [27], and we have shown that Akt expression from this
promoter leads to the selective growth of type IIb ﬁbers [17].
This analysis revealed that FGF21 was upregulated approxi-
mately 4-fold in gastrocnemius muscle at the 3 week time
point following transgene induction (Fig. 1A). Akt-mediated
regulation of FGF21 transcript in the transgenic mice was
conﬁrmed by quantitative real-time PCR (QRT-PCR)
(Fig. 1B).
FGF21 protein expression in skeletal muscle tissue samples
were examined by western blot analysis using a monoclonal
antibody, clone#84-E12, directed to FGF21. Because the he-
patic FGF21 transcript is dramatically induced by fasting
[6,7], we used 48-h fasted liver tissues as a positive control.
Comparison of gastrocnemius muscle and liver from fasted
wild-type mice revealed similar levels of FGF21 protein in
these tissues (Fig. 1C).by PI3-kinase inhibitor in cultured C2C12 myocytes. Representative
F21 in C2C12 myocytes culture media and cell lysates pretreated with
nmol/L) or vehicle.
Y. Izumiya et al. / FEBS Letters 582 (2008) 3805–3810 3809We next examined the eﬀects of Akt1 activation on FGF21
protein expression using skeletal muscle-speciﬁc Akt1 trans-
genic mice. FGF21 protein expression was robustly upregu-
lated in gastrocnemius muscle following 3 weeks of Akt1
transgene induction (Fig. 1D). Serum FGF21 concentration
was determined by FGF21-speciﬁc ELISA. Serum levels of
FGF21 were also increased by the induction of the Akt1 trans-
gene in skeletal muscle compared with control mice (Fig. 1E).
These results indicate that activation of Akt1 signaling in skel-
etal muscle lead to increase in circulating and tissue-resident
FGF21 levels.3.2. FGF21 is upregulated by Akt1 in C2C12 myocytes
To examine changes in gene expression in cultured myocyte
in response to Akt1 overexpression, diﬀerentiated C2C12 myo-
cytes were transfected with Adeno-bgal or Adeno-myrAkt1 for
16 h and microarray analysis was performed. FGF21 tran-
script was markedly upregulated in C2C12 cells treated with
Adeno-myrAkt1 (Fig. 2A). The upregulation of FGF21 tran-
script was conﬁrmed by QRT-PCR (Fig. 2B).
FGF21 protein expression levels in culture media and cell ly-
sates were examined by Western blot analysis (Fig. 2C).
FGF21 protein expression was induced 7-fold in Adeno-myr-
Akt1-treated C2C12 myocytes cell lysates compared with con-
trol. FGF21 protein in culture medium was increased 4-fold by
overexpression of constitutively active Akt1 (Fig. 2D).3.3. FGF21 expression is upregulated by insulin in a PI3-
kinase-dependent manner in cultured C2C12 myocytes
To examine the regulation of FGF21 expression by insulin, a
hormone known to naturally induce Akt activation. C2C12
myocytes were treated with physiological levels of insulin
(10 nmol/L) or vehicle in the presence or absence of pre-treat-
ment with the PI3-kinase inhibitor LY294002. FGF21 expres-
sion in the cell lysate and the culture media was signiﬁcantly
increased in response to insulin stimulation (Fig. 3). Pretreat-
ment with LY294002 inhibited both basal and insulin-stimu-
lated FGF21 expression. These results indicate that FGF21
protein is produced in cultured myocytes and is a downstream
target of PI3-kinase/Akt1 activation.4. Discussion
Since its identiﬁcation by Nishimura et al. as a member of
FGF super family, it has generally been assumed that
FGF21 is predominantly expressed in liver, and a number of
recent reports describing the exceptionally dynamic regulation
of FGF21 mRNA expression in liver [6–8] have conﬁrmed
these initial observations. Nevertheless, FGF21 has also been
detected in pancreas and in cells of various origins, suggesting
that the FGF21 expression proﬁle may indeed be broader than
initially thought [28].
In the present study, we examined for the ﬁrst time skeletal
muscle expression of FGF21 transcript and protein using
monoclonal antibodies raised against the full length FGF21.
We found that in skeletal muscle FGF21 protein expression
is essentially comparable to that in fasted liver. Because hepa-
tic FGF21 transcript is upregulated by fasting [6,7], these re-
sults indicate that skeletal muscle can be an important
source of FGF21 production.In this study, we also demonstrated that FGF21 expression
in skeletal muscle is upregulated upon activation of the PI3-
kinase/Akt1 signaling pathway. We found that both FGF21
mRNA and protein were induced by Akt1 overexpression
or insulin stimulation in skeletal muscle cells. Conversely,
insulin-stimulated FGF21 expression was inhibited by incu-
bation with a PI3-kinase inhibitor. Under these conditions
we also detected FGF21 protein in the media. Furthermore
FGF21 protein levels in the media were increased following
transduction with an activated Akt transgene or treatment
with insulin, and reduced by treatment with a PI3K inhibitor,
indicating that FGF21 can be secreted by skeletal muscle cells
in PI3K/AKT-dependent fashion. Overexpression of constitu-
tively active Akt1 in the type IIb ﬁbers of transgenic mice
also led to an increase in circulating FGF21, suggesting that
the secretion of this factor from muscle may be physiologi-
cally signiﬁcant. Thus, in addition of being direct target of
PPARa in liver in response to fasting [7,8] or ketogenic diet
[6] and PPARc in adipose [9,10], FGF21 expression and
secretion in skeletal muscle can be under control of PI3K/
AKT pathway.
While in vitro FGF21 does not appear to be an insulin mi-
metic or potentiator [2], the ability of physiological levels of
insulin to induce the expression of FGF21 in muscle cells
as well as in 3T3-L1 adipocytes (data not shown), and of
FGF21 to stimulate insulin production/secretion in pancreatic
islets and b-cells [29], raises the intriguing possibility of cross-
talk between these metabolic hormones. Indeed, FGF21 lev-
els are signiﬁcantly elevated in overtly insulinemic ob/ob
mice [8]. In healthy animals, however, insulin levels are low
during fasting and peak after feeding, whereas FGF21
expression is regulated in the opposite manner [7,8]. Further-
more, to exert its anti-hyperglycemic in vivo eﬀects, FGF21 is
likely to function as an insulin ‘‘sensitizer’’ since it eﬀectively
lowers insulin levels in diabetic animals, and improves total
insulin sensitivity in glucose tolerance tests [28]. Thus, addi-
tional studies on the interplay between insulin and FGF21
under normal physiological conditions and in diseased states
are warranted.
Myogenic Akt signaling is preferentially activated by resis-
tance training, which leads to the growth of type IIb muscle
ﬁbers that are referred to as fast/glycolytic [30–32]. We re-
cently reported, that this system of Akt1 transgene activation
in skeletal muscle of mice leads to the hypertrophy of type
IIb, but not type I or IIa, muscle and the upregulation of gly-
colytic pathways, whereas oxidative pathways are decreased
[17]. We also reported that Akt1-induced type IIb ﬁber
growth in obese mice leads to appreciable reductions in fat
mass and a normalization of metabolic parameters. These
metabolic improvements result, at least in part, from mus-
cle-induced changes in the phenotypic and transcriptional
proﬁle of the liver that promote hepatic fatty acid oxidation
and ketone body production. Based upon the ﬁndings of
the current study, we speculate that FGF21 released from
skeletal muscle may be one of the critical factors involved
in this inter-tissue communication. Consistent with this
hypothesis, the phenotype of myogenic Akt1 transgene acti-
vation in obese mice is similar to the eﬀects of FGF21 admin-
istration to diabetic rodents and non-human primates
[2,4,6,7]. Furthermore, FGF21 induces transcription of en-
zymes and transporters required for hepatic fatty acid oxida-
tion, lipogenesis and ketogenesis [5–8], and the same
3810 Y. Izumiya et al. / FEBS Letters 582 (2008) 3805–3810transcript changes are also observed in the liver of skeletal
muscle-speciﬁc Akt1 transgenic mice [17].
Here, we provide evidence that FGF21 is an Akt1-mediated
skeletal muscle-derived secreted protein or myokine. These
ﬁndings support the hypothesis that stimulators of Akt1 sig-
naling in skeletal muscle, such as resistance training exercise,
could attenuate obesity-related metabolic disorders through
production and secretion of metabolic-regulatory myokines.
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